Brokerages Set OptimizeRx Corp. (NASDAQ:OPRX) PT at $21.00

OptimizeRx Corp. (NASDAQ:OPRX) has earned an average rating of “Moderate Buy” from the nine brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $21.00.

OPRX has been the subject of several research reports. Zacks Research downgraded shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 15th. UBS Group set a $23.00 price target on OptimizeRx in a research report on Friday, October 10th. JMP Securities boosted their price target on OptimizeRx from $20.00 to $23.00 and gave the company a “market outperform” rating in a research note on Friday, October 10th. Stephens reduced their price objective on OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating for the company in a research note on Monday, November 17th. Finally, Citigroup reiterated an “outperform” rating on shares of OptimizeRx in a research report on Friday, October 10th.

Hedge Funds Weigh In On OptimizeRx

A number of large investors have recently bought and sold shares of OPRX. Harvest Investment Services LLC acquired a new stake in OptimizeRx in the 3rd quarter worth about $3,441,000. Worth Venture Partners LLC purchased a new position in shares of OptimizeRx in the third quarter valued at approximately $220,000. Virtus Advisers LLC acquired a new stake in shares of OptimizeRx in the third quarter worth approximately $516,000. Qube Research & Technologies Ltd purchased a new stake in shares of OptimizeRx during the third quarter worth approximately $381,000. Finally, Parkman Healthcare Partners LLC raised its stake in OptimizeRx by 0.4% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company’s stock valued at $10,447,000 after purchasing an additional 2,188 shares during the last quarter. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Stock Down 1.9%

Shares of NASDAQ OPRX opened at $12.60 on Tuesday. OptimizeRx has a 52-week low of $3.99 and a 52-week high of $22.25. The firm has a market capitalization of $234.86 million, a price-to-earnings ratio of 32.12 and a beta of 1.09. The stock has a 50 day moving average price of $13.90 and a 200 day moving average price of $15.82. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.05 and a current ratio of 3.05.

OptimizeRx (NASDAQ:OPRX) last posted its earnings results on Thursday, November 6th. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.17. The business had revenue of $26.07 million for the quarter, compared to the consensus estimate of $23.83 million. OptimizeRx had a net margin of 0.03% and a return on equity of 6.37%. Sell-side analysts expect that OptimizeRx will post -0.33 earnings per share for the current year.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.